Bristol-Myers Squibb Company (BMY) stock prices updated...
 

Bristol-Myers Squibb Company stock price

Bristol-Myers Squibb Company latest news:


  • 08/16/2017 14:49:08

    Urban Outfitters and Agilent climb; Bristol-Myers skids

    Urban Outfitters and Agilent Technologies trade higher while Bristol-Myers Squibb and Helmerich & Payne slip

  • 08/15/2017 14:55:21

    Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal

    Bristol-Myers Squibb Co. shares declined in the extended session Tuesday after the drugmaker said one of the endpoints of a kidney cancer drug study was not met. Bristol-Myers Squibb shares fell 2.5% to $56.40 after hours. The company said that while a late-stage study of its use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/03/2017 14:14:52

    Bristol-Myers to buy IFM Therapeutics for $300 million, and potential contingent payments

    Bristol-Myers Squibb Co. announced Thursday a deal to buy privately-held biotechnology company IFM Therapeutics for $300 million, and contingent payments of up to $1.01 billion. The acquisition gives Bristol-Myers rights to preclinical programs, STING (stimulator of interferon genes) and NLRP3 agonist, which are focused on enhancing the innate immune response for treating cancer. IFM will also be entitled to additional payments of up to $1.01 billion for each of the first products from the two programs if certain development, regulatory and sales milestones are achieved. The deal is expected to close during the third quarter of 2017. "The addition of STING and NLRP3 agonist programs broadens our ability to investigate additional pathways across the immune system and complements our immuno-oncology portfolio," said Bristol-Myers's Chief Scientific Officer Thomas Lynch. Bristol-Myers's stock, which was inactive in post-market trade, has gained lost 5.0% year to date through Thursday, while the SPDR Health Care Select Sector ETF has run up 15.6% and the S&P 500 has climbed 10.4%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/27/2017 10:43:43

    UPDATE 3-Bristol-Myers shares slump after failed AstraZeneca drug trial

    July 27 (Reuters) - Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen.

  • 07/26/2017 06:11:15

    BRIEF-Bristol-Myers Squibb’s Orencia receives second European Commission approval

    Bristol-myers Squibb Co(BMY). * Bristol-Myers Squibb’S Orencia receives second European Commission approval in less than a year – new approval for treatment of active psoriatic arthritis1. * Approval was based on results from two randomized, double-blind, placebo-controlled studies PSA-i and PSA-ii Source text for Eikon: Further company coverage:

  • 07/14/2017 14:28:37

    BRIEF-Bristol-Myers Squibb Co says Laurie Glimcher notified co that she will retire from board

    Bristol-Myers Squibb Co(BMY). * Bristol-Myers Squibb Co(BMY) - ‍on July 10, 2017, Laurie H. Glimcher, notified co that she will retire from board of directors effective July 21, 2017​. * Says also effective July 21, 2017, size of board will be set at ten directors - SEC Filing Source text: [http://bit.ly/2vmaTAq] Further company coverage:

  • 07/12/2017 14:11:00

    3 Dividend Stocks That Thrive in Market Crashes

    Sales at Johnson & Johnson, Wal-Mart, and Bristol-Myers Squibb could outperform their peers in a market crash, and that could help investors beat the market.

  • 06/13/2017 14:09:51

    BRIEF-Bristol-Myers Squibb declares quarterly dividend of $0.39/shr

    * Bristol-Myers Squibb Co says declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation Source text for Eikon: Further company coverage:

  • 06/05/2017 14:24:26

    BRIEF-Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer

    Bristol-myers Squibb Co(BMY). * Bristol-Myers Squibb(BMY) announces new collaboration to evaluate combination therapy in colorectal cancer. * Entered into a clinical research collaboration with Novartis Source text for Eikon: Further company coverage:

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |